Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TV-1106 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| recombinant human growth hormone | ACTIVE_COMPARATOR | Daily subcutaneous dose |
| TV-1106 | EXPERIMENTAL | Titration dose levels of TV-1106 |
| Name | Type | Description |
|---|---|---|
| TV-1106 | DRUG | - |
| Recombinant human growth hormone | DRUG | Subcutaneous once daily |
Inclusion Criteria: * Patient agrees to provide written informed consent and to comply with the study protocol after reading the informed consent and discussing the study with the investigator. * Males and females between 23 and 65 years of age must have a confirmed diagnosis of adult GHD, either a...
TV-1106 is an investigational small molecule being developed for the treatment of Growth Hormone Deficiency. It is intended to address this endocrine condition, which affects adults. The drug is currently in clinical development and has not been approved for use.
TV-1106 is being developed by Teva Pharmaceutical Industries Limited, a company traded on the stock exchange under the ticker TEVA. The drug is currently in Phase 2 clinical development for Growth Hormone Deficiency.
TV-1106 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. A Phase 2 clinical trial for the drug has been completed, but it remains in the clinical development process.
TV-1106 has one completed Phase 2 clinical trial, identified as NCT01811576. This trial, titled "Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency," enrolled 52 participants across multiple countries including the United States, Czechia, Germany, Greece, Hungary, Israel, Serbia, Slovakia, and Slovenia.
TV-1106 is a distinct investigational drug candidate developed by Teva Pharmaceutical Industries Limited. It is not known to be the same as any other marketed or approved medication. It is being studied specifically for Growth Hormone Deficiency.